Daneshmend T K, Homeida M, Kaye C M, Elamin A A, Roberts C J
Gut. 1982 Oct;23(10):807-13. doi: 10.1136/gut.23.10.807.
The pharmacokinetics of metronidazole 500 mg orally were determined in patients with hepatosplenic schistosomiasis and normal controls in the Sudan, and in cirrhotics and normal controls in Bristol. Plasma metronidazole levels were above the minimum inhibitory concentration of most susceptible anaerobic bacteria for four to six hours post-dose in all groups. Liver disease did not markedly influence the disposition of single oral doses of metronidazole. Cirrhotics showed some prolongation of metronidazole half-life, and somewhat greater metronidazole concentrations 24 hours after the dose. Concentrations of the oxidative metabolite of metronidazole were lower in Sudanese patients and normal controls than in normal British subjects. In chronic liver disease adjustment of metronidazole dosage is probably not required provided renal function is unimpaired.
在苏丹的肝脾型血吸虫病患者及正常对照者，以及布里斯托尔的肝硬化患者及正常对照者中，测定了口服500毫克甲硝唑后的药代动力学。给药后，所有组血浆甲硝唑水平在四至六小时内均高于大多数易感厌氧菌的最低抑菌浓度。肝脏疾病并未显著影响单次口服剂量甲硝唑的处置。肝硬化患者甲硝唑半衰期有所延长，给药24小时后甲硝唑浓度略高。苏丹患者及正常对照者中甲硝唑氧化代谢物的浓度低于英国正常受试者。在慢性肝病中，只要肾功能未受损，可能无需调整甲硝唑剂量。
